Saxat fr Readeye
Earlier today, Cinclus announced the initiation of its phase III HEEALING 1 (Healing of Erosive Esophagitis with unique Acid control using Linaprazan Glurate) study following positive feedback from regulatory authorities.
The phase III study (HEEALING 1 & HEEALING 2) will serve as the cornerstone for European approval, conducted in close alignment with commercial partner Zentiva.
We will closely monitor the progression of the study, with topline data in H2 2026e likely to serve as the most significant catalyst yet for shareholder value creation. We reiterate our fair value base case of SEK50 per share (bull: SEK80, bear: SEK15).
H2 2026 känns kanske avlägset. Jag har i vilket fall tagit en liten position med ett GAV under bear scenariot SEK 15.
Du måste logga in eller registrera dig för att svara på tråden.
